TSX-V:IBO • CA91360F1099
The current stock price of IBO.CA is 0.005 CAD. In the past year, price decreased by -66.67%.
ChartMill assigns a technical rating of 1 / 10 to IBO.CA. When comparing the yearly performance of all stocks, IBO.CA is a bad performer in the overall market: 98.77% of all stocks are doing better.
Over the last trailing twelve months IBO.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 22.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.85% | ||
| ROE | -542.4% | ||
| Debt/Equity | 6.33 |
Universal Ibogaine, Inc. engages in developing ibogaine based drug franchise to treat addiction and related mental health issues. The company is headquartered in Calgary, Alberta. The company went IPO on 2017-06-21. The firm is transforming addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorders. The firm is engaged in developing a holistic addiction treatment protocol at its Kelburn Recovery Center (located near Winnipeg, Manitoba), which, paired with the planned ibogaine detox protocol, is intended to treat addiction and improve the lives of individuals and families affected by addiction. Ibogaine is a naturally occurring molecule derived from the root bark of the iboga tree and other plants. The company is a potent and serious medical psychedelic which has addiction interrupting properties. Ibogaine targets multiple receptors across multiple sites in the brain and metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for about 1-4 months, associated with elimination of addictive cravings.
UNIVERSAL IBOGAINE INC
(c/o Suite 600 - 815 8th Avenue SW
Calgary ALBERTA CA
Employees: 0
Phone: 14038701841.0
Universal Ibogaine, Inc. engages in developing ibogaine based drug franchise to treat addiction and related mental health issues. The company is headquartered in Calgary, Alberta. The company went IPO on 2017-06-21. The firm is transforming addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorders. The firm is engaged in developing a holistic addiction treatment protocol at its Kelburn Recovery Center (located near Winnipeg, Manitoba), which, paired with the planned ibogaine detox protocol, is intended to treat addiction and improve the lives of individuals and families affected by addiction. Ibogaine is a naturally occurring molecule derived from the root bark of the iboga tree and other plants. The company is a potent and serious medical psychedelic which has addiction interrupting properties. Ibogaine targets multiple receptors across multiple sites in the brain and metabolizes into noribogaine, a serotonin re-uptake inhibitor that remains in the body for about 1-4 months, associated with elimination of addictive cravings.
The current stock price of IBO.CA is 0.005 CAD. The price decreased by -50% in the last trading session.
IBO.CA does not pay a dividend.
IBO.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
UNIVERSAL IBOGAINE INC (IBO.CA) has a market capitalization of 1.56M CAD. This makes IBO.CA a Nano Cap stock.